Background. Since 1977 when TACE was introduced
for the first time it became a standard treatment
for nonresectable HCC without vascular invasion or
extrahepatic disease. TACE is also performed for other
indications, such as colorectal metastases, cholangiocarcinoma,
neuroendocrine tumors and etc.
Material/methods. the evaluation of interventional
therapy with DEB-TACE of 8 patients each with
unrespectable HCC, cholangiocarcinoma, neuroendocrine
metastatic carcinoma. A comparison of therapy-
associated complications performed.
Results. We analyzed results of DEB-TACE performed
in our Hospital since 2014. DEB-TACE was
technically successful in all patients. A total of 21
DEB-TACE procedure was performed in 8 patients
during the 2-year period. Two patients (20%) had
five treatments, 1 patient (15%) had four treatments,
4 patients (50%) had two treatments and 1 (15%)
had one treatment. Pain, nausea, fever and fatigue
were the most common side effects following DEBTACE,
with a frequency of 76%, 33%, 57% and
71% respectively.
Conclusions. The current results show DEB-TACE
to produce beneficial tumor response and to have
exceptionally low complication rates.